Propuestabiotecnológicaparael tratamientodel cáncer de cérvix uterino…
191
2. Soto-‐Vázquez, R.;
Análisis epistemiológico de la construcción conceptual a partir del modelo de
curvas para un desarrollo biotecnológico
; Tesis deMaestría, Universidad Nacional Autónoma
deMéxico;MéxicoD.F., 2000.
3. Patente presentada: Rangel-‐Corona, R., et al. Composición de un producto antineoplásico e
inmunorregulador y su uso para el tratamiento de cáncer cérvico uterino. Expediente:
MX/a/2008/008681.
4. Corona, T.; Rangel, R.; Hernández,M.; Baeza, I.; Ibánez,M.;Weiss, B. Characterizationof cationic
liposomes having IL-‐2 expressed on their external surface, and their affinity to cervical cáncer
cells expressing the IL-‐2 receptor. Journal of DrugTargeting
,
17(7),
496-‐501 (2009).
5. Mule, J.; Shu, S.; Rosenberg, S. The anti-‐tumor efficacy of lymphokine-‐activated killer cells and
recombinant interleukin2 invivo. Journal of Immunology
135
, 646-‐652 (1985).
6. Kondapaneni, M.; McGregor, J.; Salvemini, D.; Laubach, V.; Samlowski, W. Inducible nitric oxide
synthase (iNOS) is not required for IL-‐2-‐induced hypotension and vascular leak syndrome in
mice. Journal of Immunotherapy
31
,
325-‐333 (2008).
7. Bao, A.; Phillips, W.; Goins, B.; Zheng, X.; Sabour, S.; Natarajan, M. F.; Woolley, F.; Zavaleta, C.;
Otto, R. Potential use of drug carried-‐liposomes for cancer therapy via direct intratumoral
injection. International Journal of Pharmacy
316
, 162-‐169 (2006).
8. Kepczyński, M.; Nawalany, K.; Kumorek, M.; Kobierska, A.; Jachimska, B.; Nowakowska, M.
Which physical and structural factors of liposome carriers control their drug-‐loading
efficiency?. Chemical Physical Lipids
155
,
7-‐15 (2008).
9. Pellequer, Y.; Ollivon, M.; Barratt, G. Formulation of liposomes associated with recombinant
interleukin-‐2: effect on interleukin-‐2 activity. Biomedicine & Pharmacotherapy
58
, 162–167
(2004).
10. Fahr, A.; Van Hoogevest, P.; May, S.; Bergstrand, N.; Leigh, M. Transfer of lipophilic drugs
between liposomal membranes and biological interfaces: Consequences for drug delivery
.
European Journal of Pharmaceutical Sciences
26
, 251–265 (2005).
11. Konigsberg, P.; Godtel, R.; Kissel, T.; Richer, L. The development of IL-‐2 conjugated liposomes
for therapeutic purposes. Biochemical andBiophysicsActa
1370
, 243-‐251 (1998).
12. Bien, E.; Balcerska, A. Serumsoluble interleukin2 receptor alpha inhuman cancer of adults and
children: a review. Biomarkers
13
, 1-‐26 (2008).
13. Rangel-‐Corona, R.; Rodríguez-‐Cruz, L.; Flores-‐Flores, G.; Gómez-‐Ruiz, C.; Soto-‐Cruz, I.;Mendoza-‐
Rincon, J.F.; Weiss-‐Steider, B. Differential expression of the two components of the
Interleukin-‐2 receptor in cervical cancer cells.MonduzzieEditors
3
,
1239-‐1243 (1998).
14. Rangel-‐Corona, R.; Corona-‐Ortega, T.; del Río-‐Ortiz, I.; Nieves-‐Ramírez,M.;Morán-‐Bañuelos, H.;
González-‐Tenorio, O.; Cáceres-‐Cortés, J.; Weiss-‐Steider, B. Cationic liposomes bearing IL-‐2 on
their external surface inducedmice leukocytes to kill human cervical cancer cells in vitro, and
significantly reduced tumor burden in immunodepressed mice. Journal of Drug Targeting
19(2),
79–85 (2011).
15. Ibáñez,M.; Gariglio, P.; Chávez, P.; Santiago, R.;Wong, C.; Baeza, I. Spermidine-‐condensedDNA
and cone-‐shaped lipids improve delivery and expression of exogenous DNA transfer by
liposomes. Biochemical Cellular Biology
74
, 633-‐643 (1996).
16. Acosta Gutiérrez, J.; Juárez López, R.; Velasco Lomas, I.; Gil Alegre, M. E.; Rangel-‐Corona, R.;
Weiss-‐Steider, B.; Soto Vázquez, R.; CoronaOrtega, T. Estudios de estabilidad farmacéutica de
un sistema constituidopor unproducto antineoplásico e inmunoregulador para el tratamiento
del cáncer cérvicouterino. RevistaPortuguesadeFarmácia, P-‐B21 (2011).
17. International Conference on Harmonisation of technical requirements for registration of
pharmaceuticals for human use. ICHQ1B. Stability testing: Photostability testing of new drug
substances andproducts ICHharmonised tripartiteguideline. 1996
18. International Conference on Harmonisation of technical requirements for registration of
pharmaceuticals for human use. ICH Q1A(R2) Stability testing of new drug substances and
products. 2003.
